Mast cell driven immunometabolism as a therapeutic entry point in ESCC
Frontiers in Cell and Developmental Biology · 11.05.2026 · 14
DOI: 10.3389/fcell.2026.1830394 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 11.05.2026. Verfasst von Zhifeng Qu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Cancer Institute, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science an…. Die Arbeit nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Esophageal squamous cell carcinoma (ESCC) remains one of the most aggressive epithelial malignancies, with most patients deriving only modest benefit from surgery, chemoradiotherapy, or immune checkpoint inhibition. Recent studies suggest that tumor metabolic reprogramming and immune dysfunction evolve together and reinforce one another, yet the causal links between these processes remain only partially understood. Mast cells (MCs) represent a stromal population that has received more attention. Although associated with allergic reactions, tissue repair, and inflammatory responses under normal physiology, MCs in ESCC frequently occupy stromal, vascular and hypoxic zones where metabolic stress is most pronounced. This spatial distribution suggests that MCs actively shape tumor metabolic states through the release of lipid mediators, including prostaglandins, leukotrienes, and platelet activating factor (PAF). These mediators amplify lipid metabolic programs in tumor cells and contribute to an immunosuppressive environment in which dendritic cell priming is attenuated, and cytotoxic T cell (CTL) function is progressively impaired. MC-derived cytokines and proteases further remodel the extracellular matrix and reorganize stromal architecture, collectively facilitating the invasion of malignant cells into adjacent tissue. Single cell and spatial transcriptomic analyses have revealed substantial heterogeneity among tumor-infiltrating MCs, indicating that distinct phenotypic subsets engage divergent metabolic and immune circuits and that only a subset may be functionally tumor permissive. These findings have generated increasing interest in therapeutic strategies targeting MC-linked mediators, inhibiting lipid metabolic enzymes, or integrating metabolic modulation with immune checkpoint therapy. A rigorous mechanistic understanding of how MCs coordinate metabolic and immune remodeling in ESCC may ultimately support biomarker-guided patient stratification and inform novel therapeutic combinations capable of overcoming resistance to current treatment modalities.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Cancer Institute, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, Henan, China.
- State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, China.
- Precision Medicine Laboratory, School of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, Henan, China.
- Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, Henan Key Laboratory of Cancer Epigenetics, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan,…
Zitieren
APA
Qu, Z., Zheng, X., Zhao, A., Wang, P., Gao, S., & Yin, Q. (2026). Mast cell driven immunometabolism as a therapeutic entry point in ESCC. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1830394
Vancouver
Qu Z, Zheng X, Zhao A, Wang P, Gao S, Yin Q. Mast cell driven immunometabolism as a therapeutic entry point in ESCC. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.1830394
BibTeX
@article{Qu2026,
author = {Qu, Zhifeng and Zheng, Xuewei and Zhao, Anshun and Wang, Pei and Gao, Shegan and Yin, Qinan},
title = {Mast cell driven immunometabolism as a therapeutic entry point in ESCC},
journal = {Frontiers in Cell and Developmental Biology},
year = {2026},
volume = {14},
doi = {10.3389/fcell.2026.1830394}
}
EUVIMED